ACADIA Pharmaceuticals (ACAD) The Citizens Life Sciences Conference 2026 summary

Commercial performance and financial position

• Achieved over $1 billion in combined net sales from two commercial assets, with 2024 guidance at $1.25 billion midpoint.

• Cash flow positive with over $800 million in cash and no debt, supporting both commercial and pipeline investments.

• NUPLAZID saw 9% volume growth last year, driven by renewed direct-to-consumer campaigns and increased community awareness.

• DAYBUE stabilized after initial plateau, with renewed growth following a 30% field force expansion and new formulation launch.

• Persistency for DAYBUE is strong, with 55% of patients remaining on therapy at 12 months and over 45% at 18 months.

Pipeline and clinical development updates

• Remlifanserin phase II trial for Alzheimer's disease psychosis expected to read out between August and October 2024.

• Lessons from prior trials are being applied to optimize patient selection, outcome measures, and rater training for remlifanserin.

• ACP-211, a deuterated ketamine metabolite, is in early clinical development for major depressive disorder, aiming for rapid onset and improved tolerability.

• GABA alpha-3 program for essential tremor is completing phase I, with phase II proof-of-concept study planned for late 2024 or early 2025.

• ACP-2591, a new Rett syndrome asset, is preparing for clinical testing and offers higher brain penetration than trofinetide.

Market expansion and product innovation

• NUPLAZID growth is primarily volume-driven, with a small price benefit, and expansion efforts target both community and long-term care settings.

• DAYBUE STIX, a new formulation, addresses administration challenges and is expected to reach an incremental 400 patients.

• DAYBUE is available to 6,000 diagnosed Rett patients in the US, with about 1,000 currently on therapy and 2,000 having tried it.

• International expansion for DAYBUE faces regulatory hurdles in Europe, with a re-examination underway after initial CHMP rejection.

• Business development remains a priority to further broaden the portfolio.